

Appl. No. 09/807,575
Amdt. dated Jun. 23, 2006
Reply to Office action of Mar. 23, 2006

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A diagnostic kit agent for detection of a human cancer cell that expresses glypican-1 at least one of human breast cancer and pancreatic cancer, comprising: a binding molecule selected from the group consisting of an antibody and an antibody fragment that binds to one of human glypican-1 and to human syndecan-1, and optionally a reporting molecule attached to the binding molecule such that a detection method allows detection of the cancer by detection of the presence of the binding molecule via detection of the reporting molecule; and an information associated with the binding molecule that binding of the binding molecule to a cell is indicative of a human cancer cell that expresses glypican-1.
2. (Original) The diagnostic agent of Claim 1, wherein the binding molecule comprises an antibody.
3. (currently amended) The diagnostic agent of Claim 2, wherein the antibody is used to detect glypican-1 or syndecan-1 in a body fluid.
4. (currently amended) The diagnostic agent of Claim 2, wherein the antibody is used to image glypican-1 or syndecan-1.
5. (currently amended) A therapeutic kit composition comprising a therapeutic agent at a concentration effective to slow growth of at least one of human breast cancer cells and pancreatic human cancer cells identified to express glypican-1, wherein the agent comprises a molecule selected from the group consisting of an antibody and an antibody fragment that affects glypican-1 by one of binding to an extracellular region of human glypican-1, cleaving an extracellular region of human glypican-1, and suppressing expression of an extracellular region of human glypican-1, and an information associated with the molecule that binding of the binding molecule to the cancer cells slows growth of the cancer cells.

Appl. No. 09/807,575
Amdt. dated Jun. 23, 2006
Reply to Office action of Mar. 23, 2006

6. (Previously presented) The composition of Claim 5, wherein the molecule comprises an antibody the binds to the extracellular region of glypican-1.
7. (Withdrawn) The therapeutic agent of Claim 5, wherein the molecule comprises an enzyme that digests a portion of the extracellular region of glypican-1.
8. (Withdrawn) The therapeutic agent of Claim 5, wherein the molecule comprises a nucleic acid molecule that suppresses expression of the extracellular region of glypican-1.
9. (Withdrawn) A method for diagnosing human cancer comprising the steps of contacting a molecule that binds to one of glypican-1 and syndecan-1 with either a body fluid or body tissue, and detecting the molecule bound to glypican-1 or to syndecan-1.
10. (Withdrawn) The method of Claim 9, wherein the binding molecule comprises an antibody.
11. (Withdrawn) The method of Claim 10, wherein the antibody is used to detect glypican-1 or syndecan-1 in a body fluid.
12. (Withdrawn) The method of Claim 10, wherein the antibody is used to image glypican-1 or syndecan-1.
13. (Withdrawn) A method of slowing growth of human cancer cells comprising administering a molecule that affects glypican-1 by one of binding to an extracellular region of glypican-1, cleaving an extracellular region of glypican-1 and suppressing expression of an extracellular region of glypican-1.
14. (Withdrawn) The method of Claim 13, wherein the molecule comprises an antibody the binds to the extracellular region of glypican-1.
15. (Withdrawn) The method of Claim 13, wherein the molecule comprises an enzyme that digests a portion of the extracellular region of glypican-1.
16. (Withdrawn) The method of Claim 13, wherein the molecule comprises a nucleic acid molecule that suppresses expression of the extracellular region of glypican-1.

Appl. No. 09/807,575
Amdt. dated Jun. 23, 2006
Reply to Office action of Mar. 23, 2006

17. (New) The diagnostic kit of claim 1 wherein the human cancer cell is a pancreatic cancer cell or a breast cancer cell.
18. (New) The therapeutic kit of claim 5 wherein the human cancer cells are pancreatic cancer cells or breast cancer cells.